(DR-TB) Patient Diagnose and Treatment | Gull Sima Story

Two-year-old Gull Sima is weighed by the MSF nurse Aziza Khushal at the Médecins Sans Frontières (MSF) drug-resistant tuberculosis (DR-TB) hospital in Kandahar city, Kandahar Province, Afghanistan. MSF checks family members of TB and DR-TB patients in order to see if they have symptoms of the disease.

MSB141919

To Report An Asset

If you think this image is in any way inappropriate, please report it, by including its URN/identifying code and a brief description of your concern in sending an email to [email protected]

Linked assets

Bibi Amina and her nine year old grandaughter Sayeeda on TB ward.jpg

30 year old Bibi Amina and 28 and 2 year and 3 month old Gull Sima.jpg

video consent 30 year old Bibi Amina and 28 and 2 and 3 month old Gull Sima.MOV

Diagnose and Treatment for Patients with Drug-Resistant Tuberculosis (DR-TB) | Kandahar TB Hospital

Video consent Bibi Amina and her nine year old grandaughter Sayeeda on TB ward.MOV

Add to lightbox

Add to cart

Unique Identifier Code / URN MSB141919

Date taken / Date Recorded 10/03/2022 12:00 AM

Country Afghanistan

Detailed location KANDAHAR

Commissioning section MSF-NETHERLANDS

Photographer / videographer / producer Lynzy Billing

Usage Rights (MSF) External Media, MSF Fundraising, MSF Publications, Social Media

Formal Consent Copy available yes

Editor's rating ★★★ (F)

Maximum Size 5760px × 3840px 5.84 MB

Additional Information / Shotlist MSF works in partnership with the Ministry of Public Health to diagnose and treat patients with drug-resistant tuberculosis (DR-TB). The project aims to ensure patients with TB have access to quality, free and effective treatment. In April 2021, MSF inaugurated the hospital, which includes a laboratory, outpatient clinic and 24-beds for inpatients suffering from DR-TB and comorbidities, and those who develop severe side effects after taking DR-TB medication. MSF also provides mental health support and undertakes health promotion activities in the hospital.

Multidrug-Resistant Tuberculosis